Skip to main content
. Author manuscript; available in PMC: 2015 Jul 15.
Published in final edited form as: Sci Transl Med. 2014 Aug 20;6(250):250ra116. doi: 10.1126/scitranslmed.3009706

Fig. 2. Clinical pathology and clinical scoring in MARV-infected cynomolgus monkeys.

Fig. 2

NP-718m–LNP treatment effectively abrogates clinical signs of MARV-Angola infection when administered 30 to 45 min, 24 hours, 48 hours, or 72 hours after infection. MARV-mediated liver dysfunction either is completely prevented in NP-718m–LNP–treated animals (n = 4 per treatment group) or manifests transiently with delayed onset and reduced severity. (A) ALT activity. (B) AST activity. Data are group means ± SD. (C and D) Retention of (C) prothrombin time (PT) [*P = 0.0011 (30–45 min Tx delay), *P = 0.0011 (24 h Tx delay), *P = 0.0004 (48 h Tx delay), *P < 0.0001 (72 h Tx delay), two-way ANOVA, with Bonferroni correction for pairwise comparisons] and (D) activated partial thromboplastin time (APTT) [*P = 0.0193 (1 h Tx delay), *P = 0.0034 (24 h Tx delay), *P = 0.0226 (48 h Tx delay), *P = 0.0176 (72 h Tx delay), two-way ANOVA, with Bonferroni correction for pairwise comparisons] indicates protection against HF coagulopathy. Data are group means ± SEM. (E) Clinical scores for each individual within each group after MARV challenge.